FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
|Articles|August 2, 2021
FDA Approves GSK’s Treatment for Chronic Rhinosinusitis with Nasal Polyps
Author(s)BioPharm International Editors
GSK announced that FDA has approved a new indication for Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5.
Advertisement
GlaxoSmithKline (GSK) announced on July 29, 2021 that FDA has approved Nucala (mepolizumab) as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This is a new indication for mepolizumab, which is a monoclonal antibody that targets interleukin-5 (IL-5).
Mepolizumab is the first IL-5 therapy approved as an add-on treatment in the United States for adults with CRSwNP to target eosinophilic inflammation. This new indication is for the add-on maintenance treatment of CRSwNP in adult patients 18+ with inadequate response to nasal corticosteroids.
In the US, mepolizumab is approved for four indications in eosinophil-driven diseases to date:
- Biologic therapy indicated for patients 6+ with severe eosinophilic asthma,
- Biologic therapy indicated for adults with eosinophilic granulomatosis with polyangiitis,
- Biologic therapy indicated for patients 12+ with hypereosinophilic syndrome, and
- Biologic therapy indicated for adults with CRSwNP.
Approximately, two to four percent of the US population is affected by CRSwNP. The disease is characterized by raised eosinophil levels in which nasal polyps develop in the sinuses and nasal cavity. Chronic symptoms of CRSwNP include nasal obstruction, loss of smell, facial pressure, and nasal discharge.
“More than [five] million people in the US suffer with chronic rhinosinusitis with nasal polyps and today’s approval provides these patients with the first anti-IL-5 treatment option and an alternative to surgery to help reduce symptoms of this disease,” said Hal Barron, chief scientific officer and president of R&D, GSK. “GSK is committed to exploring the role of IL-5 inhibition in eosinophil-driven diseases to help address unmet needs of patients.”
The approval of mepolizumab as a treatment for CRSwNP is based on data from the pivotal SYNAPSE study, which explored the effect of mepolizumab vs. placebo in more than 400 patients with CRSwNP.
Source:
Advertisement
Related to this article
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5